Related Experiment Videos
Cardiac effects of standard-dose halofantrine therapy
P A Matson1, S P Luby, S C Redd
1Division of Field Epidemology, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
The American Journal of Tropical Medicine and Hygiene
|March 1, 1996
Summary
Standard-dose halofantrine hydrochloride, an antimalarial, moderately prolonged the corrected QT interval (QTc) in Plasmodium falciparum patients. While no severe arrhythmias occurred, careful patient selection is advised due to potential cardiac risks.
Area of Science:
- Pharmacology
- Cardiology
- Infectious Diseases
Background:
- Halofantrine hydrochloride is an antimalarial drug.
- Cardiac arrhythmias have been linked to halofantrine use.
- Dega (Montagnard) refugees are often treated for Plasmodium falciparum infections.
Purpose of the Study:
- To investigate the cardiac effects of standard-dose halofantrine (24 mg/kg).
- To assess the risk of halofantrine-associated cardiac arrhythmias using QTc interval prolongation.
Main Methods:
- A study was conducted on 48 Dega refugees treated for Plasmodium falciparum.
- Electrocardiograms (ECGs) were used to measure the rate-corrected QT interval (QTc).
- Regression analysis was performed to evaluate predictive factors for QTc lengthening.
Main Results:
- Standard-dose halofantrine was associated with a mean QTc lengthening of 0.44 sec(1/2).
- Two patients showed a QTc increase over 25%, but none exceeded 0.55 sec(1/2).
- Pretreatment ECGs showed poor prediction of QTc lengthening during therapy.
Conclusions:
- Standard-dose halofantrine can prolong the QTc interval, indicating a potential risk for cardiac arrhythmias.
- Pre-existing cardiac conditions and pretreatment ECGs are important considerations for patient evaluation.
- Clinicians must carefully assess patient risk, including cardiac history and alternative treatments, before prescribing halofantrine.